<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">Meanwhile, the FDA has approved convalescent plasma as a treatment option for critically ill COVID-19 patients [
 <xref ref-type="bibr" rid="CR8">8</xref>]. The optimal dose and time point of application, as well as the clinical benefit of convalescent therapy, needs further investigation in larger well-controlled trials. Therefore, prospective randomized trials are planned in Germany and in the United States to answer the question whether convalescent plasma could serve as a treatment option for COVID-19 patients.
</p>
